Surgeon struck with same cancer as her patients reflects: 'I never imagined'

When Dr. Anne Peled, a 37-year-old breast cancer surgeon and mother of three, was struck by the same cancer as her patients, her world changed.
Source: ABC News: Health - Category: Consumer Health News Tags: GMA Source Type: news

Related Links:

Publication date: Available online 21 January 2019Source: Journal of Clinical NeuroscienceAuthor(s): Satish Krishnamurthy, Jie Li, Alexa Bodman, Chaozai Zhang, Yilei Yang, Jing AnAbstractAdvances in therapies for breast cancer with cerebral metastases has been slow, despite this being a common diagnosis, due to limited drug delivery by the blood brain barrier. Improvements in drug delivery for brain metastasis to target the metastases and bypass the blood brain barrier are necessary. In our study, we delivered an inhibitor of chemokine receptor 4 by convection enhanced delivery in a hyperosmotic solution to prevent brain m...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Authors: Fontes-Sousa M, Amorim M, Salta S, Palma De Sousa S, Henrique R, Jerónimo C Abstract Notwithstanding the marked progress in breast cancer (BC) management, it still constitutes the most common malignancy in women and a major cause of morbidity and mortality, thus remaining a major health issue worldwide. Most BC cases are hormone receptor (HR) positive (luminal A or B molecular subtypes) and endocrine treatment (ET) is an important therapeutic modality at all disease stages. Nevertheless, despite substantial improvements in BC patient outcome, effectiveness of ET is limited, as up to 40% of patients ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In conclusion, shikonin is a potential anti‑tumor drug for breast cancer. PMID: 30664166 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
(Bloomberg) — DNA testing company 23andMe Inc. said it has gotten the green light from the U.S. Food and Drug Administration to offer consumers a test for a hereditary colorectal cancer syndrome. 23andMe said it will now be able to tell customers whether they have two genetic variants that influence MUTYH-associated polyposis, a rare condition associated with an increased risk of colorectal cancer. The FDA didn’t immediately respond to a request for comment. Key Insights It’s the second test associated with cancer risk for which 23andMe has received FDA clearance. Last March, the Mountain View, Califo...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized DNA Testing onetime Source Type: news
In conclusion, the TF isoforms serve important and distinct roles in pathophysiological processes. PMID: 30664196 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
miR‑671‑3p is downregulated in non‑small cell lung cancer and inhibits cancer progression by directly targeting CCND2. Mol Med Rep. 2019 Jan 15;: Authors: Yao Y, Zhou Y, Fu X Abstract MicroRNAs (miRNAs) are implicated in the development and progression of non‑small cell lung cancer (NSCLC). A previous study suggested that miR‑671‑3p suppresses the development of breast cancer. However, the role of miR‑671‑3p in NSCLC remains largely unknown. In the present study, it was identified that miR‑671‑3p was significantly upregulated in NSCLC tissues compared with adjacent normal tissues by...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Estradiol induces cell proliferation in MCF‑7 mammospheres through HER2/COX‑2. Mol Med Rep. 2019 Jan 18;: Authors: Wu CH, Chuang HY, Wang CL, Hsu CY, Long CY, Hsieh TH, Tsai EM Abstract Cluster of differentiation (CD)44+/CD24- breast cancer cells have stem cell‑like characteristics and are potent initiators of tumorigenesis. Mammosphere cells can partially initiate breast tumorigenesis by inducing estradiol (E2)‑dependent breast cancer cells. However, the mechanisms by which E2 mediates cancer formation in MCF‑7 mammosphere (MS) cells have remained elusive. In the present study, MS cells were...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conclusions: Our results firstly indentified that high levels of MEOX1 especially nuclear staining was an independent prognostic factor for NSCLC, and it served a essential roles in the regulation of cell proliferation and colony formation in vitro. It may represent a potential target for the NSCLC treatment. PMID: 30662330 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Publication date: Available online 21 January 2019Source: European Journal of Surgical OncologyAuthor(s): Ojala Kaisu, Tuomo J. Meretoja, Mattson Johanna, Marjut H.K. LeideniusAbstractBackgroundThe aim of this study was to investigate outcome of treatment in patients over 80 years of age with early breast cancer at the time of the diagnosis with special interest in surgical treatment.Materials and methodsBreast cancer patients older than 80 years of age, treated at the Breast Surgery Unit of Helsinki University Hospital in 2005–2010 were identified from electronic patient records. Patients were followed-up until the ...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health